June 26, 2025 -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced that the European Journal of Pediatrics has published the results of a groundbreaking multicenter clinical trial evidencing positive results for the treatment of OSA in children using Vivos’ patented Daytime-Nighttime Appliance (DNA). The study importantly noted that “This is the first study demonstrating that t

June 26, 2025 -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced the publication of preclinical research by Christine Chung, MD and her team (the “Chung Lab”) at Moffitt Cancer Center in Tampa, Florida (“Moffitt”), evaluating intratumoral PV-10 in models of head and neck squamous cell carcinoma (“HNSCC”). The study, published in Molecular Cancer Therapeutics, highlights novel mechanistic findings that could support future clinical development of

-New Phase 1 clinical data for CTX310™ continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86% in LDL, with a well-tolerated safety profile- -Complete Phase 1 data presentation for CTX310 anticipated at a medical meeting in the second half of 2025- -Data update for CTX320™, targeting the LPA gene, now expected in the first half of 2026- -Preclinical in vivo cardiovascular program CTX340™ adva

Study met its primary and key secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity Safety profile consistent with previous clinical trials and no treatment-related serious adverse events reported in the study No evidence of tachyphylaxis was observed in this study over the 6-week period Management to Host Webcast and Conference Call Today at 8:00 A.M. ET June 26, 2025 -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing

ALK (ALKB:DC / OMX: ALK B) today announced the first market launch of EURneffy® 2 mg (the trade name for neffy® in the EU) in Germany. The launch of this first ever adrenaline nasal spray for timely emergency treatment of anaphylaxis represents a significant milestone for adults and children (≥30 kg) experiencing potentially life-threatening allergic reactions. With an intuitive, needle-free design, EURneffy® can help more people confidently use adrenaline when it matters most, supporting fast,

New clinical trial data with Bryn Pharma’s second-generation epinephrine nasal spray expected in Q3 2025 The trial employs an upgraded two-spray nasal spray device providing additional reliability and user experience enhancements Trial includes evaluation of pharmacokinetics (“PK”) and pharmacodynamics (“PD”) for an innovative two-doses-in-one device (“dual-dose”) product profile June 25, 2025 -- Bryn Pharma, Inc., (“Bryn”) a privately held pharmaceutical company dedicated to finding novel and

June 25, 2025 -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("Oncotelic" or the "Company"), a clinical-stage biopharmaceutical company focused on RNA-based therapeutics, today announced the publication of a peer-reviewed research article highlighting TGFB2 gene methylation as a positive prognostic biomarker for pancreatic ductal adenocarcinoma (PDAC). The paper, published in collaboration with Sapu Biosciences, LLC (“Sapu”), a wholly owned subsidiary of GMP Biotechnology Limited (“GMP Bio”), in

Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025 Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth driver for Amneal June 25, 2025 -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today highlighted positive topline results from a confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed biosimilar to XOLAIR® (omalizumab), developed by Kas

June 25, 2025 -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment has been selected for presentation at the ENDO 2025 annual meeting of the Endocrine Society, taking place July 12-15, 2025 in San Francisco, CA, USA. Oral OPK-88006 is being developed pursuant to a collaboration and license agreement between OPKO and Entera whereby the companies

Phase 1/2a clinical trial currently supported by a $3.0 million grant from the U.S. Department of Defense Trial will enroll children with high grade glioma and ependymoma June 25, 2025 -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational Ne